Parathyroid Hormone Kinetics During CRRT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-06

Study Completion Date

2020-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation continuous renal replacement therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thyroid Function in Critically Ill Patients With Acute Kidney Injury

NCT04767763

Secondary Hypothyroidism

COMPLETED

Changes of Renal Resistive Index in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.

NCT06174610

Acute Kidney Injury

RECRUITING

Plasma CO2 Removal Due to CRRT and Its Influence on Indirect Calorimetry

NCT03314363

Continuous Renal Replacement Therapy CO2 Removal Nutrition Poor +1 more

COMPLETED NA

Mineral-Homeostasis in Continuous Renal Replacement Therapy

NCT01946113

Acute Renal Failure

COMPLETED

Effect of Citrate on the Coagulation System in Patients Receiving CRRT

NCT02486614

Acute Kidney Failure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness Multi Organ Failure Renal Failure Circulatory Failure Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.

parathyroid hormone

Intervention Type DIAGNOSTIC_TEST

10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

parathyroid hormone

10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute respiratory failure
* Acute circulatory failure
* acute kidney injury treated with regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF
* continuous renal replacement therapy started no later than 48 hours after admission
* SOFA score 5 or more

Exclusion Criteria

* age less than 18 years
* acute liver failure
* hypercalcemia at admission (total calcium plasma level \> 10.6 mg/dL; total ionized calcium plasma level \> 1.35 mmol/L
* parathyroid glands disease
* end stage renal disease
* therapeutic plasma exchange
* extracorporeal membrane oxygenation
* unfavorable outcome (death) predicted within 72 hours (as assessed by investigator)
* lack of relatives consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No